170236 ⎘
Assays involving biological materials from specific organisms or of a specific nature from viruses; DNA viruses; Herpetoviridae, e.g. pseudorabies virus; Varicella-zoster virus Cytomegalovirus
CYTOMEGALOVIRUS T CELL EPITOPES AND USES THEREOF
#2DETECTION OF ANTI-VIRAL CDR3s IN NEUROBLASTOMA
#3METHODS OF DETERMINING PROGNOSIS OF SEPSIS AND TREATING SAME
#4APPLICATION OF HCMV GP34- AND GP68-SPECIFIC ANTIBODIES AND FRAGMENTS THEREOF FOR PREVENTION, THERAPY AND DIAGNOSTICS OF HCMV DISEASE
#5Methods and compositions for assessing antibody specificities
#6Inverse Agonistic Anti-US28 Antibodies
#7METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS
#8Methods and compositions for assessing antibody specificities
#9METHODS FOR TREATING AND PREVENTING CYTOMEGALOVIRUS INFECTION
#10METHOD FOR DETECTING CYTOMEGALOVIRUS (CMV) AND MEASURING AND QUANTIFYING PENTAMERIC COMPLEX USING AN INDIRECT SANDWICH ELISA
#11Assay to Differentiate Natural CMV Infection from CMV Vaccines that Lack UL144
#12METHODS OF DETERMINING PROGNOSIS OF SEPSIS AND TREATING SAME
#13METHOD FOR DIAGNOSING AND STAGING HERPESVIRUS-MEDIATED NEURODEGENERATION
#14Methods of Selecting T Cell Line and Donor Thereof for Adoptive Cellular Therapy
#15METHODS, KITS, AND PRODUCTS FOR DETECTION OF CYTOMEGALOVIRUS INFECTION
#16Methods and compositions for assessing antibody specificities
#17Inverse agonistic anti-US28 antibodies
#18METHODS AND COMPOSITIONS FOR ASSESSING ANTIBODY SPECIFICITIES
#19MVA-gH/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof
#20METHODS OF DETERMINING PROGNOSIS OF SEPSIS AND TREATING SAME
#21Methods for detection of anti-cytomegalovirus neutralizing antibodies
#22MVA-gh/gL-PC vaccine derived antibodies neutralizing human cytomegalovirus infectivity and methods thereof
#23Method for assessing risk of human cytomegalovirus active infection in body and related kit
#24Methods of selecting T cell line and donor thereof for adoptive cellular therapy
#25METHOD FOR RECOGNITION OF A PRESENCE OF AN INFECTION WITH CMV
#26Protein microarray for characterizing the specificity of the monoclonal immunoglobulins of MGUS or myeloma patients
#27COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CYTOMEGALOVIRUS INFECTIONS
#28Peptides derived from viral proteins for use as immunogens and dosage reactants
#29Anti-Human Cytomegalovirus Antibodies And Use Thereof
#30Methods for detection of anti-cytomegalovirus neutralizing antibodies
#31Genetic variant of cytomegalovirus (CMV)
#32Biomarkers for prenatal diagnosis of congenital cytomegalovirus
#33Immune suppressor and its use
#34Idiotypic antibodies and uses thereof
#35Compositions and methods for the therapy and diagnosis of cytomegalovirus infections
#36Compositions and methods for the therapy and diagnosis of cytomegalovirus
#37Biomarkers for prenatal diagnosis of congenital cytomegalovirus
#38RECOMBINANT ANTIGENS OF HUMAN CYTOMEGALOVIRUS (HCMV)
#39Compositions and methods for the therapy and diagnosis of cytomegalovirus
#40Detection of primary infections with pathogens
#41Materials and methods for inductions of immune tolerance
#42Screening methods for identifying inhibitors of herpesviral replication
#43Expression monitoring for human cytomegalovirus (HCMV) infection
#44Saliva immunoassay for detection of exposure to infectious agents
#45Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors
#46Method of using physiological markers to estimate cardiovascular risk